- Article
- Source: Campus Sanofi
- 9 Apr 2024
A Real World Case Study: Presented by Christine Skeet
This is intended for HCPs practising in Great Britain (England, Scotland, Wales) only.
Prescribing Information for SARCLISA®▼ (isatuximab) can be found via the Product Card at the bottom of the page.
In this video, you'll learn about
A case study presented by Christine Skeet of an 84 year old RRMM patient who receives SARCLISA® + Pd at 4th Line. The case study examines the practical considerations of managing an elderly patient with lytic bone disease and renal impairment.
Learn more about SARCLISA®
Overview of SARCLISA®
Find out more about SARCLISA® + Pd efficacy and safety data and dosing information.
Dosing and Administration Guide
Download a handy guide to SARCLISA dosing and administration information
Patient Booklet
Download SARCLISA® patient information.
Overview of SARCLISA®
Find out more about SARCLISA® + Pd efficacy and safety data and dosing information.
Dosing and Administration Guide
Download a handy guide to SARCLISA dosing and administration information
Patient Booklet
Download SARCLISA® patient information.
Relapsed Refractory
Multiple Myeloma Product
MAT-XU-2202578 (v4.0)
Date of preparation: June 2024
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
MAT-XU-2401194 (v1.0) Date of Preparation: June 2024